<code id='7DAE5BDE7B'></code><style id='7DAE5BDE7B'></style>
    • <acronym id='7DAE5BDE7B'></acronym>
      <center id='7DAE5BDE7B'><center id='7DAE5BDE7B'><tfoot id='7DAE5BDE7B'></tfoot></center><abbr id='7DAE5BDE7B'><dir id='7DAE5BDE7B'><tfoot id='7DAE5BDE7B'></tfoot><noframes id='7DAE5BDE7B'>

    • <optgroup id='7DAE5BDE7B'><strike id='7DAE5BDE7B'><sup id='7DAE5BDE7B'></sup></strike><code id='7DAE5BDE7B'></code></optgroup>
        1. <b id='7DAE5BDE7B'><label id='7DAE5BDE7B'><select id='7DAE5BDE7B'><dt id='7DAE5BDE7B'><span id='7DAE5BDE7B'></span></dt></select></label></b><u id='7DAE5BDE7B'></u>
          <i id='7DAE5BDE7B'><strike id='7DAE5BDE7B'><tt id='7DAE5BDE7B'><pre id='7DAE5BDE7B'></pre></tt></strike></i>

          hotspot

          hotspot

          author:focus    Page View:36
          illustration of one blue dna strand
          Adobe

          The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

          Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

          advertisement

          Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more
          ASCO: AstraZeneca says CAR
          ASCO: AstraZeneca says CAR

          AdobeCHICAGO—Anext-generationCAR-Ttherapywasabletosubstantiallyshrinktumorsinpatientswithlivercancer

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

          ADAMFEUERSTEIN/STATYou’rereadingthewebeditionofASCOin30Seconds,STAT’sguidetotheAmericanSocietyofClin